News

January 21, 2021January 21, 2021

Daily Coffee Drinking Lowers Prostate Cancer Risk, Study Suggests

News

Drinking more coffee may significantly reduce a person’s risk of prostate cancer, with a nearly 1% lesser likelihood seen with each additional daily cup of coffee consumed, an analysis of ... Read more

January 19, 2021January 19, 2021

Active Surveillance Safe for Black Men With Low-risk Diagnosis, Study Finds

News

Offering Black men active surveillance to manage low-risk prostate cancer is safe and does not increase the risk of disease spreading or death more than it does for white men, ... Read more

January 14, 2021January 14, 2021

Nubeqa Prescribing Information Updated With New Survival Data

News

The prescribing information for Nubeqa (darolutamide) — used to treat men with prostate cancer that has not spread to other parts of the body — will be updated to include ... Read more

January 12, 2021January 12, 2021

Orgovyx Now Available in US for Advanced Prostate Cancer

News

A couple of weeks after its approval, Orgovyx (relugolix) is now commercially available in the U.S. for adults with advanced prostate cancer through authorized specialty distributors, the therapy’s developer, Myovant ... Read more

January 7, 2021January 7, 2021

Oral ARV-110 Shows Promise in Heavily Treated mCRPC Patients

News

ARV-110, an investigational oral therapy that degrades the androgen receptor, has a favorable safety profile and showed promising anti-tumor activity in heavily pretreated men with metastatic castration-resistant prostate cancer (mCRPC), ... Read more

January 5, 2021January 5, 2021

Long-term ADT Found to Raise Risk of Cardiovascular Death

News

Long-term exposure to androgen deprivation therapy (ADT), a common treatment for prostate cancer, is associated with worse cardiorespiratory fitness and a higher risk of cardiovascular death, a new study reports. ... Read more

December 22, 2020December 22, 2020

FDA Approves Orgovyx, Oral ADT for Advanced Prostate Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Orgovyx (relugolix), an oral form of hormone therapy by Myovant Sciences, to treat adults with advanced prostate cancer. The approval, granted ... Read more

December 17, 2020December 17, 2020

Teams Working in Advanced Cancer Win 2020 PCF Challenge Awards

News

The philanthropic organization Prostate Cancer Foundation (PCF) and the charity Movember Foundation have announced the winners of the 2020 PCF Challenge Awards, an initiative that supports promising research in the ... Read more

December 15, 2020December 15, 2020

Study Describes New Way to Place CRISPR/Cas9 Into Cancer Cells

News

Researchers have developed a new technology that can be used to deliver the gene-editing tool CRISPR/Cas9 into prostate cancer cells without the need for viral vectors, a proof-of-concept study demonstrates. ... Read more

December 10, 2020December 10, 2020

Canada Approves Lynparza for Metastatic CRPC Patients With Certain Gene Mutations

News

Canadian authorities have approved Lynparza (olaparib) as an oral treatment for people with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in BRCA or ATM genes, both of which are involved in ... Read more